US astronomy survey:
The US National Academy of Science has released its decadal survey, a much-anticipated report recommending the astronomy and astrophysics research projects that US agencies should fund over the next ten years. The report, published on 13 August, says that a space telescope that could search for clues to dark energy Pandemic over: The World Health Organization (WHO) announced on 10 August that the world is no longer experiencing an H1N1 influenza virus pandemic. An emergency committee, which convened that day, said that countries were generally not reporting out-of-season outbreaks of the flu strain, and that H1N1 would probably take on the behaviour of a seasonal flu virus. Margaret Chan, director-general of the WHO, said the pandemic had turned out better than feared because the virus hadn't mutated into a more lethal form and drug resistance hadn't developed. "We have been aided by pure good luck, " she said. 
DiSEASE FolloWS DElUGE iN pAKiSTAN
As nearly three weeks of floods in Pakistan displaced tens of millions of people and killed around 1,500, the United Nations this week warned of the spread of acute diarrhoea and water-borne diseases such as dysentery and cholera. In a report released on 16 August, the UN Office for the Coordination of Humanitarian Affairs added that the floods would have a catastrophic effect on agricultural livelihoods, with extensive damage to standing crops -such as maize (corn), cotton and rice -and stored planting seeds, including the major staple food crop wheat. The summer monsoon was exacerbated this year by an unusual jet-stream pattern in the upper atmosphere; the same weather phenomenon has been linked to the Russian heatwave and resulting peat fires.
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Student gene-testing dropped:
The University of California, Berkeley, has been barred from
NUMBER cRUNcH
The amount of land (an area the size of Benin) lost every year to desertification, according to the United Nations, which on 16 August launched a ten-year campaign to halt the advance of deserts.
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and for exoplanets should be top priority for large space activities (projects exceeding US$1 billion). See page 910 for more.
providing incoming students with personal analyses of three common genetic variants. The educational programme had drawn criticism for its handling of ethical and legal issues since its announcement in May (see Nature 465, 845-846; 2010 ). California's health department ruled on 11 August that such analyses constitute medical information, so must be conducted under a doctor's order and at a clinically certified lab. The university will now not release individual results, but will still analyse some 700 student samples received, and discuss them in bulk.
PHARMA'S NEXT BLOCKBUSTER?
A new generation of hepatitis C drugs specifically targets the virus. A generation of drugs with the potential to cure hepatitis C is set to flood the market. This month, Vertex Pharmaceuticals, based in Cambridge, Massachusetts, and drug behemoth Merck, headquartered in Whitehouse Station, New Jersey, both released promising results from late-stage clinical trials of their leading drugs against the hepatitis C virus (HCV).
The virus, which infects liver cells and can cause cirrhosis and liver cancer, affects about 3% of the world's population. Currently, half of the patients with HCV are cured by a course of an immune-boosting protein and a general antiviral, although the treatment can have serious side effects. Merck's drug boceprevir and Vertex's telaprevir both block HCV's protease enzyme and -combined with the standard treatment -cured 66% and 72% of patients respectively in phase III trials.
If the drugs are approved by mid-2011, as their manufacturers hope, they will take the early lead in an HCV-drug field that could grow to be worth US$15 billion by 2017, according to Irena Melnikova, a life-sciences analyst at TVM Capital in Boston, Massachusetts. Competitors in a crowded field (see chart) are developing other protease inhibitors, as well as drugs that target HCV's polymerase enzyme, and its NS5A protein, which is involved in replication and viral assembly. See go.nature.com/rkncZt for more. Nobel prizes won, publications in Nature and Science, and highly cited researchers in various subject categories. In individual disciplines, Princeton University in New Jersey took top spot for mathematics and the University of California, Berkeley, led in chemistry.
Pharma deal: Generic drugs maker Aspen Pharmacare, based in Durban, South Africa, will buy the drugs manufacturing unit of Australian company Sigma Pharmaceuticals for A$900 million (US$806 million). Aspen, which is 19% owned by pharmaceutical giant GlaxoSmithKline, headquartered in London, and is Africa's largest drugs manufacturer, wanted to expand its position in the Australian generics market. It announced the deal on 16 August. Ranbaxy resignation: The chief executive of India's biggest drug maker, Ranbaxy, resigned unexpectedly last week, citing differences of opinion with parent company Daiichi Sankyo, New Jersey, and MIT, based in Cambridge. A123, meanwhile, says that it has ended a deal with Chrysler to provide batteries for the firm's electric cars, although it promised a new deal with an unnamed car manufacturer. public offering. In a US Securities and Exchange Commission filing dated 16 August, the company says that it would use the proceeds for further research and development relating to its sequencing technology, which reads off DNA sequences at single-molecule resolution in real time (see Nature 465, 145; 2010). It would also use the money to boost marketing, sales and manufacturing of its sequencers, planned for commercial launch later this year. based in Tokyo. Atul Sobti (pictured) had led Ranbaxy, a major player in the generic drugs market and headquartered in Gurgaon, for little more than a year. He took the helm after the US Food and Drug Administration accused the company of falsifying safety data. Ranbaxy announced net profits of 3.3 billion rupees (US$71 million) for the year's second quarter, down 50% on the previous year but above analysts' expectations.
